Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Convertible Series B Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2023		$ 6,509	$ 47,148,361	$ (48,558,111)	$ (1,403,241)
Balance, shares at Dec. 31, 2023		6,508,897
Warrants exercised		$ 11	26,169		26,180
Warrants exercised, shares		11,000
Additional paid in capital from warrants issued under advisory agreement			15,543		15,543
Additional paid in capital from warrants issued as debt discount			97,465		97,465
Common stock issued from agreements		$ 75	200,175		200,250
Common stock issued from agreements, shares		75,000
Net loss				(2,120,651)	(2,120,651)
Balance at Mar. 31, 2024		$ 6,595	47,487,713	(50,678,762)	(3,184,454)
Balance, shares at Mar. 31, 2024		6,594,897
Balance at Dec. 31, 2023		$ 6,509	47,148,361	(48,558,111)	(1,403,241)
Balance, shares at Dec. 31, 2023		6,508,897
Net loss					(6,793,596)
Balance at Sep. 30, 2024	$ 2,074	$ 6,980	53,548,720	(55,351,706)	(1,793,932)
Balance, shares at Sep. 30, 2024	2,073,524	6,980,227
Balance at Mar. 31, 2024		$ 6,595	47,487,713	(50,678,762)	(3,184,454)
Balance, shares at Mar. 31, 2024		6,594,897
Common stock issued from agreements		$ 247	798,682		798,929
Common stock issued from agreements, shares		246,724
Net loss				(2,917,710)	(2,917,710)
Additional paid in capital from warrants issued under consulting agreement			44,853		44,853
Balance at Jun. 30, 2024		$ 6,842	48,331,248	(53,596,472)	(5,258,382)
Balance, shares at Jun. 30, 2024		6,841,621
Common stock issued from agreements		$ 138	384,694		384,832
Common stock issued from agreements, shares		138,606
Net loss				(1,755,234)	(1,755,234)
Additional paid in capital from warrants issued under consulting agreement			65,426		65,426
Debt discount on mandatory conversion of convertible promissory notes to Series B Preferred Stock			(165,577)		(165,577)
Conversion of convertible promissory notes to Series B Preferred Stock	$ 2,074		4,932,929		4,935,003
Conversion of convertible promissory notes to Series B Preferred Stock, shares	2,073,524
Balance at Sep. 30, 2024	$ 2,074	$ 6,980	53,548,720	(55,351,706)	(1,793,932)
Balance, shares at Sep. 30, 2024	2,073,524	6,980,227
Balance at Dec. 31, 2024	$ 4,281	$ 6,990	58,856,089	(56,799,612)	2,067,748
Balance, shares at Dec. 31, 2024	4,280,939	6,990,227
Warrants exercised		$ 186	(186)
Warrants exercised, shares		186,166
Common stock issued from agreements		$ 40	112,453		112,493
Common stock issued from agreements, shares		39,471
Net loss				(2,278,684)	(2,278,684)
Vesting of restricted stock units			356,922		356,922
Balance at Mar. 31, 2025	$ 4,281	$ 7,216	59,325,278	(59,078,296)	258,479
Balance, shares at Mar. 31, 2025	4,280,939	7,215,864
Balance at Dec. 31, 2024	$ 4,281	$ 6,990	58,856,089	(56,799,612)	2,067,748
Balance, shares at Dec. 31, 2024	4,280,939	6,990,227
Net loss					(6,091,898)
Balance at Sep. 30, 2025	$ 3,897	$ 9,886	65,162,668	(62,891,510)	2,284,941
Balance, shares at Sep. 30, 2025	3,896,907	9,886,294
Balance at Mar. 31, 2025	$ 4,281	$ 7,216	59,325,278	(59,078,296)	258,479
Balance, shares at Mar. 31, 2025	4,280,939	7,215,864
Warrants exercised		$ 720	1,002,271		1,002,991
Warrants exercised, shares		720,359
Net loss				(1,690,418)	(1,690,418)
Vesting of restricted stock units			173,042		173,042
Coversion of Series B Preferred Stock to common stock	$ (384)	$ 384
Coversion of Series B Preferred Stock to common stock, shares	(384,032)	384,032
Issuance of common stock pursuant to shelf registration statement		$ 1,539	4,998,460		4,999,999
Issuance of common stock pursuant to shelf registration statement, shares		1,538,461
Offering costs			(490,799)		(490,799)
Balance at Jun. 30, 2025	$ 3,897	$ 9,859	65,008,252	(60,768,714)	4,253,294
Balance, shares at Jun. 30, 2025	3,896,907	9,858,716
Common stock issued from agreements		$ 13	33,900		33,913
Common stock issued from agreements, shares		13,518
Net loss				(2,122,796)	(2,122,796)
Vesting of restricted stock units			160,865		160,865
Offering costs			(40,335)		(40,335)
Issuance of restricted stock units		$ 14	(14)
Issuance of restricted stock units, shares		14,060
Balance at Sep. 30, 2025	$ 3,897	$ 9,886	$ 65,162,668	$ (62,891,510)	$ 2,284,941
Balance, shares at Sep. 30, 2025	3,896,907	9,886,294

Neuraxis, INC 10-Q